SynthesisEye (London, England)2025
Ocular manifestations of Juvenile Systemic Lupus Erythematosus: a systematic review.
Synthesis in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Dermatological Indicators of Systemic Autoimmune Disease: Clinical Links to Ocular Involvement.Dermatology practical & conceptual · 2026Review
- Vision-Threatening Juvenile Lupus Retinopathy: A Report of Two Cases and Review of the Literature.Mediterranean journal of rheumatology · 2026Article
- Resolved Central Serous Chorioretinopathy Mimicking Hydroxychloroquine Toxicity: A Case Series and Literature Review.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Juvenile-onset Systemic Lupus Erythematosus (JSLE) is a chronic multifactorial autoimmune disease with multiple system involvement, affecting children and adolescents. Ocular manifestations are rare and can range from mild to severe. JSLE impacts quality of life and prognosis. However, the impact JSLE has on children's ocular health remains an underexplored area. This systematic review aims to consolidate existing evidence on ocular manifestations in JSLE. A systematic search of MEDLINE and ScienceDirect was conducted until October 2024. Eligible studies focused on children and adolescents with JSLE presenting ocular symptoms. Joanna Briggs Institute critical appraisal tools for each study were employed for quality assessment. Forty-two studies evaluating ocular manifestations in JSLE patients were included. Among those were 29 case reports and case series with 34 patients in total, 4 cross-sectional studies, with a total of 210 patients, 155 of whom had ocular manifestations, and 9 cohort studies, with a total of 2696 patients enrolled and 212 of them reporting ocular manifestations (7.8%). Results were categorized by affected ocular structures: external, anterior, or posterior segment. Neuro-ophthalmological and drug-induced manifestations were described separately. Retinal involvement was the most often reported. Notable manifestations included dry eye disease, uveitis, vaso-occlusive retinopathy, and corticosteroid-induced cataracts. Ocular symptoms often served as the initial indication of disease onset. Heightened awareness and standardized assessments are necessary for management of ocular manifestations. Further research is needed to comprehensively elucidate the underlying mechanisms and pathogenesis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.